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Ferroptosis-inducing agents compromise
in vitro human islet viability and function
Antonio Bruni1,2, Andrew R. Pepper1, Rena L. Pawlick1, Boris Gala-Lopez3, Anissa F. Gamble1,2, Tatsuya Kin 1,
Karen Seeberger2, Gregory S. Korbutt2, Stefan R. Bornstein4, Andreas Linkermann 5 and A. M. James Shapiro1,2
Abstract
Human islet transplantation has been hampered by donor cell death associated with the islet preparation procedure
before transplantation. Regulated necrosis pathways are biochemically and morphologically distinct from apoptosis.
Recently, ferroptosis was identiﬁed as a non-apoptotic form of iron-dependent regulated necrosis implicated in
various pathological conditions. Mediators of islet oxidative stress, including glutathione peroxidase-4 (GPX4), have
been identiﬁed as inhibitors of ferroptosis, and mechanisms that affect GPX4 function can impact islet function and
viability. Ferroptosis has not been investigated directly in human islets, and its relevance in islet transplantation
remains unknown. Herein, we sought to determine whether in vitro human islet viability and function is compromised
in the presence of two distinct ferroptosis-inducing agents (FIA), erastin or RSL3, and whether these effects could be
rescued with ferroptosis inhibitors, ferrostatin-1 (Fer-1), or desferrioxamine (DFO). Viability, as assessed by lactate
dehydrogenase (LDH) release, revealed signiﬁcant death in erastin- and RSL3-treated islets, 20.3% ± 3.8 and 24.4% ±
2.5, 24 h post culture, respectively. These effects were ameliorated in islets pre-treated with Fer-1 or the iron chelator,
desferrioxamine (DFO). Stimulation index, a marker of islet function revealed a signiﬁcant reduction in function in
erastin-treated islets (control 1.97 ± 0.13 vs. 50 μM erastin 1.32 ± 0.1) (p < 0.05). Fer-1 and DFO pre-treatment alone did
not augment islet viability or function. Pre-treatment of islets with erastin or Fer-1 did not impact in vivo engraftment
in an immunodeﬁcient mouse transplant model. Our data reveal that islets are indeed susceptible to ferroptosis
in vitro, and induction of this novel cell death modality leads to compromised islet function, which can be recoverable
in the presence of the ferroptosis inhibitors. The in vivo impact of this pathway in islet transplantation remains elusive
given the constraints of our study, but warrants continued investigation.
Introduction
The inception of the “Edmonton Protocol” by Shapiro
and colleagues, and more recent modiﬁcations and
improvements were critical in establishing islet trans-
plantation as a viable therapeutic option for select patients
with type 1 diabetes mellitus1, 2. With complete insulin-
independence up to 1 year post transplant, 5-year follow-
up of early transplant recipients demonstrated maintained
graft function with presence of C-peptide, correction of
hemoglobin A1C, and stabilization of glycemic control,
but the majority returned to modest exogenous insulin
therapy over time3. Early insights into long-term success
rates suggest that there are numerous limitations asso-
ciated with engraftment outcomes, many of which occur
during islet isolation and in the acute and peri-transplant
period.
When transplanted into the portal vein, it is estimated
that up to 70% of the transplanted islet mass is lost in the
acute and peri-transplant period, resulting from numer-
ous factors. Such factors include the instant blood-
mediated inﬂammatory reaction, hypoxia, delayed
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revascularization, and inﬂammatory cytokines4. These
events stimulate the initiation of cell death cascades,
apoptosis, and necrosis, contributing to islet loss during
the preparation procedure and within hours and days of
transplant, long before the initiation of alloimmune or
recurrent autoimmune responses5–7. In contrast to non-
immunogenic apoptosis, necrosis is increasingly recog-
nized as the most potent trigger of the immune system8.
Likely, this event is further exaggerated by human leu-
kocyte antigen (HLA) or species incompatibility9–11.
Strategies to deter early cell death could critically aug-
ment islet engraftment thereby improving long-term graft
function. Along these lines, strategies to prevent caspase-
dependent islet death, including the administration of
interleukin-1β receptor agonists12, withaferin A13, and
caspase-speciﬁc inhibitors both in vitro and in vivo have
been explored previously7, 14–16.
Non-apoptotic cell death has been identiﬁed in various
pathological conditions, including myocardial infarction,
stroke, ischemia-reperfusion injury, and many others17. In
contrast to unregulated necrosis, whereby cell death can
occur through spontaneous, “accidental” triggers like
trauma, regulated necrosis occurs through distinct bio-
chemical mediators that activate molecular machinery8.
One particular subroutine of regulated necrosis, termed
ferroptosis, is morphologically and biochemically distinct
from other forms of cell death, that it is iron-dependent
and non-apoptotic18, 19. Ferroptosis was ﬁrst described in
parallel to the identiﬁcation ferrostatin-1 (Fer-1), an
inhibitor of this cell death pathway that functioned to
prevent erastin-induced cell death8, 9, 17, 18. Erastin, a
small potent molecule capable of selectively inhibiting the
Xc-cystine/glutamate antiporter required for glutathione
(GSH) biosynthesis, induces ferroptosis17, 18. Subsequent
to intracellular GSH depletion, the GSH-dependent, lipid
repair enzyme, glutathione peroxidase 4 (GPX4), lacks the
ability to sufﬁciently repair aberrant downstream accu-
mulation of reactive oxygen species (ROS)17, 18, 20–22.
RSL3, has recently been identiﬁed as a potent GPX4-
speciﬁc inhibitor and known inducing agent of ferropto-
sis18, 21. Relative to other native tissues, islets exhibit
reduced antioxidant defences, and as a result are sus-
ceptible to the dysregulation of free radical production
and subsequent oxidative stress23, 24. Desferrioxamine
(DFO), an iron chelator has demonstrated some beneﬁt to
improving islet viability. Ferrostatins were previously
demonstrated to reduce ferroptosis-induced death in
cellular models of Huntington’s disease, periventricular
leukomalacia, kidney tubular necrosis, and acute kidney
injury17, 25. Given that key mediators of islet survivability
are also key targets that induce ferroptosis, it has yet to be
elucidated if islets are susceptible to ferroptosis-induced
cell death.
Herein, we sought to establish whether human islets
exhibit reduced islet viability and function when chal-
lenged with ferroptosis-inducing agents (FIAs), erastin, or
RSL3, in vitro. We also sought to determine whether
inhibitors of ferroptosis such as the small molecule Fer-1
could rescue human islets from the subsequent deleter-
ious effects of these agents. Given the conceived cyto-
protective effects of Fer-1 in other disease models, we
evaluated whether pre-conditioning with Fer-1 could
augment islet engraftment in an immunodeﬁcient, mar-
ginal human islet transplant model, as well as assess
whether in vitro challenge with erastin could compromise
subsequent in vivo engraftment in a full-dose transplant
model.
Results
Human islets cultured in the presence of erastin exhibit
impaired function and viability
Cell-free supernatants collected 24 h post culture
revealed signiﬁcant levels of LDH from islets challenged
with 20 or 50 μM erastin compared to supernatants from
islet cultured in CMRL alone (Fig. 1a) (20 μM erastin:
22.0% ± 4.0; 50 μM erastin: 20.3% ± 3.8, p < 0.01). When
Fig. 1 In vitro human islet viability and function is compromised in the presence of erastin. a Human islets challenged with 20 and 50 μM
erastin exhibit increased LDH release relative to non-treated control islets (p < 0.01). Data represented as percent of control. b Erastin treatment
impairs glucose-stimulated insulin secretion in human islets. (p < 0.05). Data represented as mean ± SEM. (One-way ANOVA followed by Tukey’s
multiple comparison test). Triplicate samples from at least three human pancreata
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assessed for islet function, human islets exposed to 50 μM
erastin exhibited signiﬁcantly reduced insulin-secreting
capacity in response to glucose vs. control islets (stimu-
lation index: control 1.97 ± 0.13 vs. 50 μM erastin 1.32 ±
0.1, p < 0.05) (Fig. 1b). These results indicated that islets
are sensitive to ferroptosis.
Pre-treatment with 1 μM Fer-1 and 100 μM DFO rescues
erastin-induced islet cell death
After 24 h of 20 μM erastin treatment, human islets pre-
treated with 1, 5, or 10 μM Fer-1 exhibited signiﬁcantly
reduced LDH levels as compared to islets treated with
erastin alone (p < 0.01, p < 0.001, and p < 0.001, respec-
tively) (Fig. 2a–c). Notably, in all cases, islets pre-treated
with Fer-1 exhibited no signiﬁcant difference in LDH
release compared to their erastin-treated counterparts.
Moreover, in the presence of 50 μM erastin, 24-h pre-
treatment with 1 μM Fer-1 or 100 μM DFO exhibited
signiﬁcant cytoprotection compared to erastin treatment
alone (p < 0.001 and p < 0.01, respectively) (Fig. 2d).
Similarly, islets pre-treated with 5 or 10 μM Fer-1
conferred signiﬁcant cytoprotection in the presence of 50
μM erastin as exhibited by reduced LDH release (data not
shown). These results indicate that ferroptosis in islets
can be prevented by DFO and Fer-1.
Fer-1 pre-treatment preserves sGSIS in the presence of
erastin
Since human islets treated with 50 μM erastin exhibited
signiﬁcant impairment of glucose-stimulated insulin
secretion relative to non-treated control islets, we eval-
uated whether pre-treatment with 1 μM Fer-1 or 100 μM
DFO could improve glucose-stimulated insulin secretion
(GSIS) in the presence of erastin. Human islets pre-
treatment with 1 μM Fer-1 followed by erastin treatment
preserved the insulin-secreting capacity of human islets
(stimulation index 1 μM Fer-1+ 50 μM erastin: 2.29 ±
0.06), whereas islets treated with erastin alone exhibited
reduced insulin-secreting capabilities (stimulation index
50 μM erastin: 1.35 ± 0.1) (p < 0.01) (Fig. 3). Pre-treatment
of islets with DFO followed by erastin treatment exhibited
a non-signiﬁcant preservation in insulin-secreting
Fig. 2 Assessment of LDH release of human islets pre-treated with or without Fer-1 or DFO in the presence of erastin. a–c Human islets
exhibit signiﬁcantly reduced islet cell death when pre-treated for 24 h with 1, 5, or 10 μM Fer-1 and subsequently challenged with erastin for an
additional 24 h. **p < 0.01, ***p < 0.001, ****p < 0.0001 (one-way ANOVA). d 1 μM Fer-1 and 100 μM DFO exhibited reduced LDH release in the
presence of 50 μM Fer-1 erastin relative to erastin-alone-treated islets. **p < 0.01, ***p < 0.001, ****p < 0.0001 (one-way ANOVA). Data represented as
mean ± SEM, Triplicate samples from at least three human pancreata
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capacity (stimulation index 100 μM DFO+ 50 μM erastin:
2.3 ± 0.36; p > 0.05). As anticipated, Fer-1 alone and DFO
alone-treated islets demonstrated similar insulin secretory
capacity as control islets (stimulation index control: 2.1 ±
0.14 vs. 1 μM Fer-1: 2.41 ± 0.19 vs. 100 μM DFO: 2.1 ±
0.38, p > 0.05) (Fig. 3). These data demonstrate the func-
tional relevance of ferroptosis in islets with respect to
sGSIS.
RSL3 compromises human islet viability and moderately
impairs sGSIS
To further elucidate whether FIAs could compromise
in vitro viability and function, human islets were cultured
for 24 h in the presence of an alternative known stimu-
lator of ferroptosis, RSL3, at 20 μM concentration sub-
sequent to 24 h of pre-conditioning with or without 1 μM
Fer-1 or 100 μM DFO. Cell-free supernatants from islets
cultured in RSL3 alone exhibited signiﬁcantly elevated
LDH in comparison to non-treated control islets alone
(control: 1.7% ± 0.1 vs. 20 μM RSL3: 24.4% ± 2.5, p <
0.0001). Islets pre-treated with 1 μM Fer-1 and subse-
quently challenged with 20 μM RSL3 for an additional 24
h exhibited signiﬁcantly reduced cell death in comparison
to RSL3 treatment alone (20 μM RSL3: 24.4% ± 2.5 vs. 1
μM Fer-1 ± 20 μM RSL3: 12.57% ± 1.85, p < 0.05) (Fig. 4a).
Islets pre-treated with 100 μM DFO and subsequently
challenged with 20 μM RSL3 exhibited reduced, albeit
non-signiﬁcant reduction in LDH release relative to RSL3
treatment alone (20 μM RSL3: 24.4% ± 2.5 vs. 100 μM
DFO ± 20 μM RSL3: 14.28% ± 3.2, p > 0.05) (Fig. 4a).
When evaluating the insulin-secreting capacity of islets
through sGSIS, islets challenged with 20 μM RSL3 were
not signiﬁcantly different from control islets (control:
2.35 ± 0.07 vs. 20 μM RSL3: 1.80 ± 0.23, p > 0.05). These
results indicated that ferroptosis in human islets can be
induced by type 1 (erastin) and type 2 (RSL3) ferroptosis
inducers. Induction of either type of FIAs is sensitive to
DFO and Fer-1.
Erastin, but not RSL3, treatment signiﬁcantly increases
CHAC1 mRNA expression in human islets
Twenty-four hours post treatment with 50 μM erastin
or 20 μM RSL3, human islets were collected and assessed
for messenger RNA (mRNA) expression of the
glutathione-depleting gene, CHAC1. Relative to non-
treated control islets, erastin-treated islets exhibited a
signiﬁcant upregulation of mRNA expression of CHAC1
(p < 0.01). In contrast, RSL3-treated islets revealed no
signiﬁcant difference in CHAC1 expression relative to
non-treated islets (p > 0.05) (Fig. 5). In these experiments,
we describe an easily detectable marker to differentiate
between GSH depletion-induced ferroptosis and direct
GPX4 inhibition.
Engraftment efﬁcacy of Fer-1-treated human islets
transplanted under the renal capsule of immunodeﬁcient
mice
Islet engraftment efﬁcacy of human islets pre-treated
with or without Fer-1 for 48 h was evaluated in a marginal
islet transplant mass model (500 IEQs per recipient, n= 2
control, n= 4 Fer-1). All recipients became euglycemic
subsequent to transplant in both transplant groups. Daily
non-fasting blood glucose monitoring of euglycemic
transplant recipients revealed no difference between
control and Fer-1-treated islet recipients (Fig. 6a). Intra-
peritoneal glucose tolerance tests (IPGTTs) were per-
formed on all marginal islet transplant, euglycemic
recipients 35 days post transplant. Mice in both transplant
groups exhibited a physiological response to glucose
bolus, with a prompt restoration of normoglycemia up to
120min post-dextrose infusion (Fig. 6b). Furthermore,
there was no signiﬁcant difference in mean area under the
curve (AUC) ± SEM (AUC control: 1557 ± 300.4 mmol/L/
120min vs. Fer-1: 1335 ± 100.1 mmol/L/120 min, p > 0.05,
unpaired t test, Fig. 6c). This experiment suggests that
pre-treatment of islets with the ferroptosis inhibitor, Fer-
1, does not enhance engraftment in this transplant model.
However, it cannot be excluded that more stable second
generation ferrostatins may still be beneﬁcial.
Human islets pre-treated with erastin do not exhibit
impaired engraftment
Transplant recipients of human islets pre-treated for 24
h with or without 1 μM Fer-1 and additional 24 h
Fig. 3 Fer-1 pre-treatment maintains sGSIS in human islets
treated with erastin. Human islets were pre-treated ±1 μM Fer-1 or
±100 μM DFO for 24 h and subsequently challenged ±50 μM erastin
for an additional 24 h. Subsequent to culture, islets were collected and
assessed for sGSIS. Cell-free supernatants were assessed for insulin
secretion via ELISA and expressed as stimulation index (insulin
secreted in response to 16.7 mM glucose vs. insulin secreted in
response to 2.8 mM glucose). Data represented as mean ± SEM,
triplicate samples from at least three human pancreata. **p < 0.01
(one-way ANOVA, followed by Tukey’s multiple comparison test)
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challenge with or without 50 μM erastin revealed no sig-
niﬁcant difference in restoration of euglycemia between
all transplant groups (Fig. 7a). Non-fasting, mean blood
glucose proﬁles of all four transplant groups revealed
similar glycemic trends (Fig. 7b). Recipients in all groups
reverted back to hyperglycemia upon graft recovery
nephrectomy, thus conﬁrming graft-dependent euglyce-
mia. To evaluate in vivo graft function, IPGTT was per-
formed on transplant recipients 40 days post transplant.
Islet transplant recipients from all groups revealed similar
blood glucose proﬁles post-dextrose infusion and exhib-
ited a restoration of normoglycemia within 120 min
(Fig. 7c). No discernable difference in blood glucose mean
AUC was observed between groups (Fig. 7d). These data
suggest that islet engraftment is not compromised sub-
sequent to erastin pre-treatment in this transplant
scenario.
Discussion
Strategies to ameliorate early islet loss in culture and in
the acute transplant period may positively contribute to
long-term engraftment outcomes. During organ pro-
curement, islet isolation, and transplantation, islets
experience considerable oxidative stress that contributes
to islet injury and loss. GSH has been identiﬁed as an
important intracellular antioxidant capable of mitigating
the accumulation of ROS. Erastin has demonstrated the
ability to induce ferroptosis by minimizing cystine uptake,
reducing intracellular GSH levels, thus contributing to
ferroptosis-induced cell death in various disease models17.
Moreover, the GPX4 inhibitor, RSL3 has also been iden-
tiﬁed as an additional inducing agent of ferroptosis. Given
the importance of GSH and GPX4 in islet viability and
function, the role of ferroptosis has yet to be elucidated in
islet transplantation.
The inability to resolve accumulating ROS results in
oxidative stress. It has previously been demonstrated that
considerable ROS is generated during isolation and
transplantation26, 27. Prolonged oxidative stress has been
associated with compromised islet viability and func-
tion28. As such, host antioxidant systems play an integral
role in reducing excessive ROS thus minimizing cellular
damage and impairment. Islets exhibit reduced intrinsic
antioxidant enzyme expression and activity relative to
other host tissues and in an effort to preserve islet func-
tion, the administration of exogenous antioxidants has
Fig. 4 Evaluation of in vitro human islet viability and function in the presence of the ferroptosis-inducing agent, RSL3. Human islets were
pre-treated with or without 1 μM Fer-1 for 24 h and subsequently challenged with or without 20 μM RSL3 for an additional 24 h. a Human islets
exhibit signiﬁcantly increased cell death as assessed by LDH in the presence of 20 μM RSL3. Pre-treatment with 1 μM Fer-1 or 100 μM DFO preserves
islet viability in the presence of RSL3. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (one-way ANOVA). b sGSIS evaluation of the insulin-secreting
capacity of human islets cultured alone, pre-conditioned with 1 μM Fer-1 or 100 μM DFO in the presence of 20 μM RSL3. Cell-free supernatants were
assessed for insulin secretion via ELISA and expressed as stimulation index. Data represented as mean ± SEM, triplicate samples from at least three
human pancreata
Fig. 5 Erastin, but not RSL3 treatment augments CHAC1 mRNA
expression in human islets. Human islets treated for 24 h in the
presence of 50 μM erastin exhibit a signiﬁcant increase in the
glutathione-depleting gene, CHAC1 (**p < 0.01). In contrast, 20 μM
RSL3 treatment did not signiﬁcantly elevate CHAC1 expression relative
to non-treated control islets
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provided substantial cytoprotective beneﬁt23, 24, 29. GSH, a
tri-peptide synthesized from glutamate, cysteine, and
glycine has been established as an important intracellular
antioxidant30. The exogenous administration of gluta-
mine, which contributes to glutamate synthesis, a GSH
precursors, have exhibited improved islet function31, 32.
Intra-ductal administration of glutathione precursors,
such as L-glutamine, have previously demonstrated the
ability to augment intracellular glutathione pools, and
reduce oxidative injury during human pancreatic islet
isolation32. Disruption of the cell’s glutamine-synthesizing
capacity may alternatively contribute to the cell’s demise.
In the present study, we evaluated whether human islet
viability and function could be compromised in the pre-
sence of FIAs, erastin, and RSL3. Our results revealed that
erastin and RSL3 exacerbated LDH release, indicative of
islet cell ferroptosis. Erastin exhibited the ability to impair
the insulin-secreting capacity of islets when assessed via
sGSIS, and for islets pre-conditioned with Fer-1 (or DFO),
the effect was abolished. These ﬁndings are novel, as these
studies represent ﬁrst-in-human testing of Fer-1 pathways
in human tissues, and speciﬁcally in human islets. These
observations may be attributed to erastin’s ability to
inhibit cystine uptake and contribute to subsequent GSH
depletion17, as our study revealed that human islets
exposed to erastin exhibited a signiﬁcant increase in
CHAC1 expression relative to non-treated islets. Notably,
CHAC1 mRNA levels were unaffected by DFO or Fer-1
pre-treatment (data not shown) suggesting that glu-
tathione depletion precedes the beneﬁcial effects of these
cytoprotective agents. CHAC1 expression levels may also
provide a tool to differentiate between type 1 and type 2
ferroptosis induction alongside with determination of the
intracellular GSH content. Prior studies have implicated
GSH as a crucial antioxidant alleviating oxidative stress in
islets. Glutamine, a precursor to GSH has previously been
shown to enhance insulin secretion in response to glucose
as well as reduce lipid peroxidation levels32–34. Miwa and
colleagues27 demonstrated that islets treated with various
lipid peroxidation products inhibited glucose-induced
insulin secretion. Ample evidence suggests that when
elevated in β-cells, fatty acids impair insulin gene
expression, glucose-stimulated insulin secretion, and
increase cell death35. It remains to be determined in more
detail if these fatty acids also contain polyunsaturated
fatty acids that were recently demonstrated to contribute
to ferroptosis, dependent on the molecule PEBP1. How-
ever, little is known about ferroptosis in human tissues.
In our study, human islets pre-treated with Fer-1 and
subsequently challenged with erastin exhibited improved
viability and function than islets treated with erastin. Fer-
1’s ability to mitigate the deleterious events associated
with ferroptosis has previously been demonstrated in
various cellular models, including Huntington’s disease25,
and likely accounts for improved islet viability. It is pos-
sible that impaired insulin secretion observed in our study
was a result of downstream events associated with
engagement of the Xc- antiporter through erastin treat-
ment. GPX4 is capable of reducing intracellular ROS and
requires GSH as an essential enzymatic co-factor19. Era-
stin treatment has previously demonstrated the ability to
indirectly inhibit GPX4 activity by depleting GSH levels20.
Koulajian et al.28 demonstrated improved in vitro and
in vivo β-cell function in islets over-expressing GPX4 in
the presence of lipid peroxidation products, further sub-
stantiating the necessity of GPX4 in preserving islet via-
bility. On this premise, we sought to evaluate whether
in vitro viability and function could indeed be compro-
mised in the presence of the GPx4-speciﬁc inhibitor and
FIA, RSL3. Given the importance of GPX4 in maintaining
islet function and viability, increased levels of LDH indi-
cate impaired viability. Islets challenged with RSL3 indeed
revealed reduced viability, which was rescued in the pre-
sence of the ferroptosis inhibitor, Fer-1. However, the
insulin-secreting capacity of islets exposed to 20 μM RSL3
exhibited only a modest insigniﬁcant decrease in sGSIS
relative to non-treated islets and islets pre-conditioned
with Fer-1. While this dose was capable of sufﬁciently
Fig. 6 Efﬁcacy of marginal dose human islet transplants under the renal capsule of C57BL/6 RAG−/− recipients. a Non-fasting blood glucose
measurements of euglycemic recipients post transplant. Recipients of control and 1 μM Fer-1 marginal (500 IEQs) human islets exhibited robust
glycemic control until graft retrieval (arrow). b Blood glucose prolife post-dextrose bolus of control (black, n= 2) and 1 μM Fer-1 (gray, n= 4). c Blood
glucose area under the curve (AUC) analysis did not differ between control and 1 μM Fer-1-treated islet recipients. Mice were administered 3 mg/kg
25% dextrose i.p. Blood glucose measurements were monitored at t= 0, 15, 30, 60, 90, and 120min
Bruni et al. Cell Death and Disease  (2018) 9:595 Page 6 of 10
Ofﬁcial journal of the Cell Death Differentiation Association
inducing cell death, a higher dose of RSL3 may be
required to confer impairment in insulin-secreting capa-
city, or regulated necrosis pathways other than ferroptosis
(e.g., necroptosis or pyroptosis) may be involved.
Though treatment of human islets with both FIAs
utilized in this study revealed compromised in vitro via-
bility, pre-treatment of islets with erastin prior to trans-
plant did not impair engraftment when transplanted
under the renal capsule of immune-deﬁcient recipients
with a transplant dose (1500 IEQs). Early observations in
the in vivo marginal study revealed both control islet
recipients became euglycemic in parallel to all Fer-1-
treated islet recipients. Control, Fer-1-and DFO-treated
islets exhibited similar LDH levels in vitro, suggesting
minimal cytotoxicity in culture without erastin or RSL3
treatment. An important explanation for differences
between the positive impact of Fer-1 in vitro, but not
seen in vivo, is that Fer-1 has a short half-life, and
therefore may have had limited efﬁcacy if ferroptosis was
ongoing in vivo.
Fig. 7 Efﬁcacy of full-dose (1500 IEQs) human islet transplants under the renal capsule of C57BL/6 RAG−/− recipients. a Percent euglycemia
of full-dose (1500 IEQs) human islet transplant recipients receiving islets cultured alone (control, n= 7), or challenged with 50 μM erastin (red, n= 7),
1 μM Fer-1 alone (blue, n= 7), or 1 μM Fer-1 ± 50 μM erastin (green, n= 7). b Non-fasting blood glucose measurements of human islet recipients
post transplant. Euglycemic recipients maintained glycemic control throughout the duration of engraftment until graft retrieval (arrow). Dotted line
exhibits maximum threshold of normoglycemia (≤11.1 mmol/L). Data represented as mean ± SEM per group. c Blood glucose proﬁle post-dextrose
bolus of control (black, n= 7), 20 μM erastin (red, n= 7), 1 μM Fer-1 alone (blue, n= 7), or 1 μM Fer-1 ± 50 μM erastin (green, n= 7). d Mean blood
glucose area under the curve (AUC). Mice were administered 3 mg/kg 25% dextrose i.p. Blood glucose measurements were monitored at t= 0, 15,
30, 60, 90, and 120 min. Data represented as mean ± SEM per group
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It is important to emphasize in the current study that
human islets only became available for research study
24–72 h post isolation and subsequently assessed an
additional 48 h in our experimental conditions. It is likely
that any major negative contribution of ferroptosis could
have already occurred within the unstable multi-organ
donor, during prolonged cold ischemia, and the preceding
islet isolation and culture periods. The impact we
observed in vitro therefore reﬂects a secondary wave of
inducible injury from the FIAs. This, coupled with the fact
that we recounted and compensated for any numeric loss
of human islets sustained during erastin or
RSL3 secondary culture when we transplanted the human
islets across groups, may explain why the dominant
negative impact of FIAs was seen only in vitro but masked
in vivo. The negative impact of both FIAs in vitro was
relatively modest (~15–20% inducible cell death only,
even at maximal doses). This further suggests that the
FIAs are acting through non-dominant pathways, and that
the majority of islets remain preserved. The present study
therefore does not completely deﬁne the full potential of
ferroptosis inhibition in islet transplantation, especially if
this could be applied early in the multi-organ donor, and
across all steps of transport, islet isolation and culture,
which was not addressed herein.
Utilizing Fer-1 during islet isolation and acutely post
culture may confer beneﬁt to human islets and would be
worth investigating in the experimental setting to deter-
mine its prospective clinical utility. It may also be
necessary to evaluate the potential cytoprotective effect of
Fer-1 using a more clinically relevant transplant site, like
the hepatic portal vein. Our group previously revealed
that the cytoprotective effects of the apoptosis inhibitor,
F573, conferred varying engraftment outcomes dependent
on the site of transplantation36. Moreover, this study also
revealed the necessity to administer the drug to the organ
donors and/or recipients could potentially confer
improved engraftment outcomes. In this regard, admin-
istration of Fer-1 or other more potent ferroptosis inhi-
bitors to donors or recipients may be necessary to confer
maximal beneﬁt to islet engraftment. More stable fer-
rostatins are currently being designed.
We and others, have suggested that Fer-1 exhibits lower
in vivo stability, and have developed a third-generation
ferroptosis inhibitor that exhibits improved plasma and
metabolic stability17. Expanding the utility of new gen-
eration inhibitors of ferroptosis during islet isolation to
prevent accumulated damage may be an attractive avenue
to explore. The administration of ferrostatins as a co-
therapy to islet transplant recipients or patients affected
with type 2 diabetes may also yield improved clinical
outcomes. Deterring early islet loss during isolation and
subsequent clinical transplant is critical for long-term
graft function. Utilizing novel cell death inhibitors to
diminish islet damage in vitro and in the acute transplant
period may be an attractive combination therapy to pre-
serve islet mass and improve engraftment.
Materials and methods
Erastin, RSL3, Fer-1, and DFO
Erastin and Fer-1 (Sigma, Oakville, ON) were prepared
by dissolving the drugs in phosphate buffered saline (PBS)
at a stock concentration of 10 mM. DFO (Sigma, Oakville,
ON) was prepared by dissolving the drug in water at a
stock concentration of 75 mM. RSL3 was received by the
Stockwell Laboratory (Columbia University, NY) and was
prepared by dissolving the drug in dimethyl sulfoxide
(DMSO) at a stock concentration of 40 mM. For long-
term storage, both reagents were stored at −20 °C.
Human islet isolation, puriﬁcation, and culture
Human islet preparations were isolated after family
consent to retrieve pancreas organs from deceased multi-
organ donors, as previously described37, with intent for
clinical transplantation and were only made available for
research when the islet yield fell below that of the minimal
mass required. Permission regarding the performance of
these studies was granted by the Health Research Ethics
Board at the University of Alberta (Edmonton, Alberta,
Canada), after written permission from donor families.
Human islets were cultured in clinical grade CMRL-1066
media (Media Tech, MT99-603-L) supplemented with
insulin selenium-transferrin and insulin-like growth
factor-1 at 22 °C and were received 24–72 h after
isolation.
Islet culture
Human islets were cultured in Connaught Medical
Research Laboratories (CMRL-1066) medium supple-
mented with 10% fetal bovine serum, L-glutamine (2 mM),
penicillin (50,000 units), streptomycin (50 mg), HEPES (5
mM), nicotinamide (10 mM), and sodium pyruvate (5
mM). For select erastin experiments, islets were main-
tained in CMRL ± 1, 5 or 10 μM of the ferroptosis inhi-
bitor Fer-1 (Sigma, Oakville, ON) for 24 h. Subsequently,
islets were collected, quantiﬁed, and cultured in the above
conditions ±20 or 50 μM FIA, erastin (Sigma, Oakville,
ON), for an additional 24 h. For RSL3 experiments, islets
were maintained in CMRL ± 1 μM Fer-1 for 24 h and
subsequently cultured in the aforementioned conditions
±20 μM RSL3.
Lactate dehydrogenase as a measure of cytotoxicity
Human islets were cultured in the aforementioned
conditions in non-tissue treated six-well plates (Costar,
Corning, NY). Cell-free supernatants were subsequently
collected and assessed for LDH release with the Cyto-
toxicity Detection Kit (Roche). Percentage cytotoxicity
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was calculated as per the manufacturer’s protocol using
the formula: (test LDH release− spontaneous release)/
maximal release. Test LDH release is the LDH released
after treatment with the various treatment conditions;
spontaneous release is the baseline cell LDH release; and
maximal LDH release is the release of LDH when cells are
lysed with 5% Triton-X. The data are the means of at least
three independent experiments ± SEM.
Static glucose-stimulated insulin secretion
Subsequent to 24-h culture, islets were collected from
control (CMRL only) and treatment groups and were
subjected to static GSIS (sGSIS). For each experiment, 50
islet equivalents (IEQs) from each group were incubated
in RPMI-1640 containing low (2.8 mmol/L) glucose for 1
h, followed by high (16.7 mmol/L) glucose for an addi-
tional hour. Subsequent to glucose challenge, cell-free
supernatants were collected and insulin levels were
measured by enzyme-linked immunosorbent assay (Mer-
codia, Uppsala, Sweden). Stimulation index is represented
as the ratio of insulin secreted in response to high glucose
vs. insulin secreted in response to low glucose.
Quantitative real-time PCR
RNA was extracted from islet preparations post culture
(RNeasy Mini Kit; QIAGEN). Complementary DNA was
synthesized by using the High-Capacity Reverse Tran-
scription Kit (Thermo Fisher Scientiﬁc), and relative
quantiﬁcation (RQ) was performed by using TaqMan
Gene Expression Assays (Thermo Fisher Scientiﬁc) with
SDS software on the ABI PRISM 7900HT. Validated
primer sets were as follows: PTGS2 (Hs00153133_m1),
CHAC1 (Hs00225520_m1), and GAPDH (Hs0278
6624_g1), a housekeeping gene. Analysis by RQ software
(ABI 7900HT) used the ΔΔCt method, and data were
plotted as RQ.
Diabetes induction and islet transplantation
One week prior to transplantation, immunodeﬁcient
C57BL/6 RAG−/− mice (Jackson Laboratories, Bar Har-
bor, ME, USA) 12–14 weeks of age were rendered diabetic
by chemical induction with intraperitoneal streptozotocin
(STZ) (Sigma-Aldrich Canada Co., Oakville, ON,
Canada), at 185 mg/kg in acetate phosphate buffer, pH
4.5. Diabetes was conﬁrmed when non-fasting blood
glucose levels exceeded 15 mmol/L for 2 consecutive daily
readings.
For marginal human islet transplants, 24 h post culture
± 1 μM Fer-1 islets were quantiﬁed and transplanted
under the kidney capsule at a dose of 500 IEQs ± 10% per
diabetic recipient. For full-dose human islet transplants,
islets were cultured for 24 h ± 1 μM Fer-1 and an addi-
tional 24 h ± 50 μM erastin, were collected, quantiﬁed,
and transplanted under the kidney capsule at a dose of
1500 IEQs ± 10% per diabetic recipient. From the time of
islet isolation to full-dose islet transplantation, the median
culture period was 96 h.
For all transplants, human islets were aspirated into
polyethylene (PE-90) tubing using a micro-syringe, and
centrifuged into a pellet suitable for transplantation. A left
lateral paralumbar incision was made and the left kidney
delivered. The renal capsule was incised and the islets
were infused.
Evaluation of islet graft function
Non-fasting blood glucose measurements (mmol/L)
were assessed three times weekly using a portable gluc-
ometer (FreeStyle InsuLinx, Abbott Diabetes Care Ltd.,
Oxon, UK) in the three transplant groups tested. Graft
function and reversal of diabetes was deﬁned as two
consecutive readings ≤11.1 mmol/L and maintained until
study completion. IPGTTs were conducted at study
endpoint; 35 days post transplant for marginal islet reci-
pients and 40 days post transplant in full-dose islet
transplant recipients. Mice were fasted overnight prior to
receiving an intraperitoneal 25% glucose bolus (3 g/kg).
Blood glucose levels were evaluated at baseline (time 0),
15, 30, 60, 90, and 120min post injection. Blood glucose
AUC was calculated and analyzed between transplant
groups.
Islet graft retrieval
In order to corroborate graft-dependent euglycemia,
islet transplants were retrieved by recovery nephrectomy.
Islet transplant recipients were placed under anesthesia,
and their graft-bearing kidney was exposed. Using a
LT200 Ligaclip (Johnson & Johnson, Inc., Ville St-Laur-
ent, QC, CA), the renal vessels and ureter were ligated and
the islet graft-bearing kidney was removed. Non-fasting
blood glucose measurements were monitored up to 7 days
post graft removal to conﬁrm hyperglycemia and thus
post-transplant graft function.
Statistical analysis
All data are represented as the mean ± SEM Islet via-
bility data comparisons between control and treatment
groups were analyzed through parametric one-way ana-
lysis of variance (ANOVA). Tukey’s post-hoc tests were
used following the analysis of variances for multiple
comparisons between study groups. IPGTT AUC was also
analyzed by parametric one-way ANOVA. Data was
analyzed using GraphPad Prism (GraphPad Software, La
Jolla, CA, USA). p < 0.05 was considered signiﬁcant.
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